MarketPulse

drug development

26 articles
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Pfizer's 6.4% Dividend Yield Attracts Income Investors Despite Sector Headwinds

Pfizer's 6.4% dividend yield attracts income investors, but structural challenges like patent expirations and a payout ratio exceeding 100% present execution risks.
PFEdividend yieldincome investing
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Fulcrum's Pociredir Shows Strong Hemoglobin Gains in Sickle Cell Phase 1b Trial

Fulcrum's pociredir shows strong fetal hemoglobin gains in sickle cell Phase 1b trial, with 58% of patients reaching therapeutic levels and reduced pain crises.
FULCrare diseaseclinical trial results
BenzingaBenzinga··Vandana Singh

Bristol-Myers Squibb Reports Positive Phase 2 Results for Reblozyl in Alpha-Thalassemia

Bristol-Myers Squibb's Reblozyl achieved positive Phase 2 results for Alpha-Thalassemia, showing improved hemoglobin levels and reduced transfusion needs in patients.
BMYCELGrclinical trialdrug development
GlobeNewswire Inc.GlobeNewswire Inc.··Custom Market Insights

ALS Therapeutics Market Poised to More Than Double by 2035

ALS therapeutics market to more than double by 2035, reaching $1.96 billion. Growth driven by genetic therapies, improved diagnostics, and disease awareness.
CYTKBIIBIONSAMLXrare diseasegene therapy
The Motley FoolThe Motley Fool··Jonathan Ponciano

First Turn Management Establishes $35M Stake in Clinical-Stage Biotech Terns

First Turn Management invests $35M in clinical-stage biotech Terns Pharmaceuticals, acquiring 4.03% stake. Stock surged 826% year-over-year on cancer drug trial progress.
TERNdrug developmentstock surge
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Perspective Therapeutics to Unveil 2025 Results and Clinical Pipeline Progress

Perspective Therapeutics will release 2025 financial results and clinical pipeline updates on March 16, highlighting progress in its cancer-targeting radiopharmaceutical programs.
CATXfinancial resultsclinical trials